Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion

Use of Letrozole Pretreatment With Misoprostol for Induction of Abortion in First Trimester Missed Abortion

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04590482

Enrollment

110

Registered

2020-10-19

Start date

2020-11-15

Completion date

2021-05-08

Last updated

2020-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Missed Abortion

Brief summary

this study will compare the efficacy of using letrozole pre treatment before misoprostol versus using misoprostol only in the induction of first trimester missed abortion.

Detailed description

Intervention type: drug Intervention name: letrozole then misoprostol Description :letrozole 2.5mg twice per day for 2days then misoprostol 800mcg for all patients to induce abortion Arm group label:study group Intervention type :drug Intervention name:placebo then misoprostol Description : placebo for 2days then 800mcg misoprostol to all patients to induce abortion Arm group label: control group

Interventions

DRUGletrozole

Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion

DRUGplacebo

placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

participant- care provider -investigator- outcomes assessor

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 42 Years

Healthy volunteers

Yes

Inclusion criteria

1. Maternal age more than 18 years old. 2. Gestational age less than 13 weeks confirmed by ultrasound scan on day 1 of the study. 3. Hemoglobin \>10 g/dl 4. Missed abortion

Exclusion criteria

1. Mullerian Uterine anomalies as septate, bicornuate uterus. 2. Fibroid uterus. 3. Coagulopathy. 4. Medical disorder that contraindicate induction of abortion. 5. Allergy to misoprostol or letrozole. \-

Design outcomes

Primary

Measure	Time frame	Description
Complete abortion	6 hours	incidence of complete abortion without the need of surgical evacuation among 110patients in which 55 of patients took letrozole before misoprostol and the other 55 patients took placebo before misoprostol

Secondary

Measure	Time frame	Description
surgical evacuation	6 hours	surgical evacuation for the remnants of conception among 110 patients in which 55 took letrozole before misoprostol and other 55 patients who took placebo before misoprostol

Contacts

Primary Contactshereen khedr

a.m.agdy@hotmail.com01011304478

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026